Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760005 | 1.00 | JAK2 (0.49) | JAK2JAK1USP30GPR119PRMT5 | |
| SCHEMBL6760105 | 0.94 | USP30 (0.48) | JAK2JAK1USP30GPR119PRMT5 | |
| SCHEMBL6760104 | 0.94 | USP30 (0.48) | JAK2JAK1USP30GPR119PRMT5 | |
| SCHEMBL2087497 | 0.91 | JAK2 (0.45) | JAK2JAK1USP30GPR119RORC | |
| SCHEMBL6759997 | 0.81 | USP30 (0.47) | JAK2JAK1USP30GPR119RORC | |
| SCHEMBL2090454 | 0.80 | MEN1 (0.45) | JAK2JAK1USP30GPR119RORC | |
| SCHEMBL8030926 | 0.80 | STS (0.47) | GPR119STS | |
| SCHEMBL6510132 | 0.79 | NPY2R (0.52) | MEN1KMT2ATGM2PTGDR2 | |
| SCHEMBL6760101 | 0.78 | USP30 (0.51) | JAK2JAK1USP30GPR119RORC | |
| SCHEMBL24628140 | 0.77 | USP30 (0.52) | JAK2JAK1USP30GPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | LABORATORIOS VITA, S.A. (ES) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | OXA1L, Q6ZSR9, PGC | JAK2 2027/4885JAK1 2210/4885USP30 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.